Overview

Registry of Patients Treated With Plerixafor (Mozobil®) for Haematopoietic Stem Cell Mobilization Before Autologous Transplantation

Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
The aim of this registry is to provide information, in day-to-day practice, on Plerixafor prescription modalities in France, over a 13-month period in order to address the health authorities' request.
Details
Lead Sponsor:
Genzyme, a Sanofi Company
Treatments:
JM 3100
Plerixafor